Gabapentin Tablet
Product Images NDC 16571-226

6 FDA label images from Rising Pharma Holdings, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 16571-226). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 01)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 01)
Chemical structure of gabapentin, showing a cyclohexane ring with an amino group (NH2) and a carboxyl group (COOH) attached to the same carbon, representing the molecular layout of the active ingredient gabapentin.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 02)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 02)
A line graph comparing mean pain scores over 8 weeks between two groups: a placebo group and a Gabapentin group receiving 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin scores decrease over time while placebo scores remain relatively steady.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 03)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 03)
A line graph depicting mean pain scores over 7 weeks. The X-axis represents weeks from baseline through a 3-week dose titration period and a 4-week fixed dose period, while the Y-axis shows mean pain score values from 0 to 10. The graph compares placebo with Gabapentin dosed at 1800 mg/day and 2400 mg/day, showing decreasing pain scores over time for both Gabapentin doses compared to placebo.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 04)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 04)
A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the percentage of responders in Study 1 and Study 2 between placebo (PBO) and gabapentin (GBP) groups at various dosages (3600 mg in Study 1, 1800 mg and 2400 mg in Study 2). Percentages range from 12% to 34%, with gabapentin groups showing higher responder proportions. Statistical significance markers for p < 0.01 and p < 0.001 are included.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 05)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 05)
A scatter plot chart showing percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis for three studies (Study a, Study b, Study c). The chart compares effects at daily doses of 600, 900, 1200, and 1800 mg, with data points labeled by study and dose.*
FDA Label Image

600 (E4b713f1 A833 4fc7 8a0f 696077ddc280 06)

600 (E4b713f1 A833 4fc7 8a0f 696077ddc280 06)
Label for Gabapentin Tablets, USP 600 mg oral tablets, 100 count. The product is manufactured by Graviti Pharmaceuticals Pvt. Ltd., India, and distributed by Rising Pharma Holdings, Inc., East Brunswick, NJ. The label includes storage instructions, dosage/use notice, and links to the medication guide. NDC 16571-226-01 is displayed along with barcode and revision date 03/2024.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.